{
    "id": 22194,
    "cites": 45,
    "cited_by": 2,
    "reference": [
        "Acemoglu, Daron & Joshua Linn, (2004). \"Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,\" The Quarterly Journal of Economics, vol. 119(3), pages 1049-1090, August.",
        "Angrist, Joshua D. (2001) \"Estimation of Limited Dependent Variable Models with Dummy Endogenous Regressors.\" Journal of Business & Economic Statistics 19(1):2-28.",
        "Berndt, E. R., M. K. Kyle, and D. Ling (2003): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The long shadow of patent expiration: generic entry and RX-OTC switches,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Scanner data and price indexes, University of Chicago Press.",
        "Berndt, Ernst R., Richard Mortimer, Ashoke Bhattacharjya, Andrew Parece, and Edward Tuttle. \"Authorized generic drugs, price competition, and consumers\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2 welfare.\" Health Affairs 26, no. 3 (2007): 790-799.",
        "Blume-Kohout, Margaret E., and Neeraj Sood. \"Market size and innovation: Effects of Medicare Part D on pharmaceutical research and development.\" Journal of public economics 97 (2013): 327336.",
        "Bokhari, Farasat AS. \"What Is the Price of Pay-to-Delay Deals?.\" Journal of Competition Law and Economics 9, no. 3 (2013): 739-753.",
        "Bound, John, David A. Jaeger, Regina Baker (1995) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Problems with Instrumental Variables Estimation when the Correlation Between the Instruments and the Endogenous Explanatory Variables is Weak,\" Journal of the American Statistical Association, 90 (June): 443-450. 1995 Branstetter, Lee G., Chirantan Chatterjee & Matthew Higgins, (2011) \"Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry,\" NBER Working Papers 17188.",
        "Furlow, Bryant. \"Public outcry over US generic drug price hikes.\" The Lancet Respiratory Medicine 3.11 (2015): 840.",
        "Bulow, J. (2004) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093The Gaming of Pharmaceutical Patents,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d in Innovation Policy And The Economy 145, 159-73 (Adam B. Jaffe et al. eds.) Caves, R. E., M. D. Whinston, M. A. Hurwitz, A. Pakes, and P. Temin (1991): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Patent expiration, entry, and competition in the U.S. pharmaceutical industry,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Brookings Papers on Economic Activity, 1\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c66.",
        "Drake, K. M., Starr, M. A., & McGuire, T. (2014). Do\" Reverse Payment\" Settlements of BrandGeneric Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay? (No. w20292). National Bureau of Economic Research.",
        "Dorsney, Kenneth (2012) ANDA Litigation: Strategies and Tactics for Pharmaceutical Patent Litigators, American Bar Association.",
        "Edlin, A. S., Hemphill, C. S., Hovenkamp, H. J., & Shapiro, C. (2013). Activating Actavis. Antitrust Magazine, Fall.",
        "Edlin, Aaron S. and Hemphill, C. Scott and Hovenkamp, Herbert J. and Shapiro, Carl, The Actavis Inference: Theory and Practice (February 5, 2015). Columbia Public Law Research Paper No. 14459.",
        "January 2010. (http://www.ftc.gov/os/2010/01/100112payfordelayrpt.pdf.) Filson, Darren & Oweis, Ahmed, 2010. \"The impacts of the rise of Paragraph IV challenges on startup alliance formation and firm value in the pharmaceutical industry,\" Journal of Health Economics, Elsevier, vol. 29(4), pages 575-584, July.",
        "Finkelstein, Amy. \"Static and dynamic effects of health policy: Evidence from the vaccine industry.\" Quarterly Journal of Economics 119.2 (2004): 527-564.",
        "Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. May 19 2004;291(19):2344-2350.",
        "Goldman DP, Joyce GF, Karaca-Mandic P. (2006a) Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. American Journal of Managed Care. 12(1): 21-28.",
        "Goldman DP, Joyce GF, Lawless G, Crown WH, Willey V. (2006b) Benefit design and specialty drug use. Health Affairs. 25(5):1319-1331.",
        "Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. Jul 4 2007;298(1):61-69.",
        "Goldman, Dana P., Darius N. Lakdawalla, Jesse D. Malkin, John Romley, and Tomas Philipson. \"The benefits from giving makers of conventional \u00c3\u00a2\u00e2\u0082\u00ac\u00cb\u009csmall molecule\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2drugs longer exclusivity over clinical trial data.\" Health Affairs 30, no. 1 (2011): 84-90.",
        "Grabowski, Henry G., and John M. Vernon. \"Returns to R&D on new drug introductions in the 1980s.\" Journal of Health Economics 13.4 (1994): 383-406.",
        "Grabowski, Henry. \"Are the economics of pharmaceutical research and development changing?.\" Pharmacoeconomics 22.2 (2004): 15-24.",
        "Grabowski, Henry G., and Margaret Kyle. 2007. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Competition and Market Exclusivity Periods in Pharmaceuticals.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Managerial and Decision Economics vol. 28, 491-502.",
        "Hall, Bronwyn H., Adam Jaffe and Manuel Trajtenberg \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Market Value and Patent Citations\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics Vol. 36, No. 1 (Spring, 2005), pp. 16-38 Hemphill, Scott (2006) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Paying for Delay: Pharmaceutical Patent Settlement as a Regulatory Design Problem\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d, New York University Law Review 81:1553 Hemphill, C. Scott, (2007) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093 Drug Patent Settlements Between Rivals: A Survey\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Available at SSRN: http://ssrn.com/abstract=969492 or http://dx.doi.org/10.2139/ssrn.969492 Hemphill, Scott and Bhaven Sampat (2011) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093When Do Generics Challenge Drug Patents?\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Journal of Empirical Legal Studies 613.",
        "Hemphill, C. Scott, and Bhaven N. Sampat. \"Evergreening, patent challenges, and effective market life in pharmaceuticals.\" Journal of Health Economics 31.2 (2012): 327-339.",
        "Higgins, Matthew J., and Stuart JH Graham. \"Balancing innovation and access: patent challenges tip the scales.\" Science 326, no. 5951 (2009): 370-371.",
        "Howard DH, Bach PB, Berndt ER, Conti RM. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pricing in the Market for Anticancer Drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d The Journal of Economic Perspectives. 2015 Feb 1;29(1):139-62.",
        "Huskamp, H. A., J. M. Donohue, C. Koss, E. R. Berndt, and R. G. Frank (2008): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Generic Entry, Reformulations, and Promotion of SSRIs,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Pharmacoeconomics, 7, 603\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c616.",
        "Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. Oct 9 2002;288(14):1733-1739.",
        "Jaffe, A. and M. Trajtenberg (eds.) Patents, Citations and Innovations. Cambridge, MA: The MIT Press, 2002.",
        "Kesselheim, Aaron S., Lindsey Murtagh, and Michelle M. Mello. \"\u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pay for Delay\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Settlements of Disputes over Pharmaceutical Patents.\" New England Journal of Medicine 365.15 (2011): 14391445.",
        "Lanjouw, Jean O. and Mark Schankerman (2001) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Characteristics of Patent Litigation: A Window on Competition,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics, Vol. 32, No. 1, pp. 129-151 Lakdawalla, Darius, and Tomas Philipson. \"Does Intellectual Property Restrict Output? An Analysis of Pharmaceutical Markets.\" Journal of Law and Economics 55, no. 1 (2012): 151-187.",
        "Lakdawalla, Darius, and Neeraj Sood. \"Health insurance as a two-part pricing contract.\" Journal of public economics 102 (2013): 1-12.",
        "Lanthier, M., Miller, K. L., Nardinelli, C., & Woodcock, J. (2013). An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c2011. Health Affairs, 32(8), 1433-1439.",
        "Lichtenberg, F. R. and G. Duflos (2009): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Time Release: The Effect of Patent Expiration on U.S. Drug Prices, Marketing, and Utilization by the Public,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Manhattan Institute Medical Progress Report, 11.",
        "Miceli, Thomas J. \"Economics of the law: Torts, contracts, property, litigation.\" (1997). National Academy of Sciences.",
        "Panattoni, Laura E. \"The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.\" Journal of health economics 30, no. 1 (2011): 126-145.",
        "Reiffen, D., Ward, M., 2005. Generic drug industry dynamics. Review of Economics and Statistics. 87, 37-49.",
        "Saha, A., Grabowski, H., Birnbaum, H., Greenberg, P., Bizen, O., 2006. Generic competition in the US pharmaceutical industry. International Journal of the Economics of Business. 13, 15-38.",
        "Shapiro, Carl (2003) \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Antitrust Limits to Patent Settlements,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND Journal of Economics Vol.",
        "Spier, Kathryn E. \"Litigation.\" Handbook of law and economics 1 (2007): 259-342.",
        "Staiger, D. and J.H. Stock (1997): \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Instrumental Variables Regression with Weak Instruments,\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Econometrica, 65, 557 \u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0080\u009c 586.",
        "Tefferi A, Kantarjian H, Rajkumar SV, et al. \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093In support of a patient-driven initiative and petition to lower the high price of cancer drugs.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Mayo Clinic Proceedings. 2015.",
        "Wooldridge Jeffrey, M. (2002) Econometric Analysis of Cross Section and Panel Data.",
        "Yin W. Market incentives and pharmaceutical innovation. Journal of Health Economics. 2008;27(4):1060-77."
    ]
}